As official media partners, VJHemOnc is excited to bring you the latest news from the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT), which was held virtually from 14-17 of March, 2021.

View all videos

EBMT 2021

The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
March 14-17, 2021

Blinatumomab and inotuzumab in children with R/R B-ALL, w/ Sarah Tasian of @ChildrensPhila: http://ow.ly/8cpu50EF8UI

@PennMedicine @PennMedNews @AACR #AACR21 #HemOnc #Leukemia #Leusm #ALLsm #ImmunoOnc

Ken Anderson closing #COMy21 with his vision for the near future of new #myeloma treatments that will deploy classical MM drugs and targeted agents to induce immunogenic cell death that is then amplified with novel #immune agents #mmsm

3

That is a wrap to yet another fantastic Controversies in #myeloma meeting. Congrats to ⁦@Mohty_EBMT⁩ and co-chairs and looking forward to all being together in person next year #COMy21 #mmsm

Load More...

EBMT 2021

The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
March 14-17, 2021

As official media partners, VJHemOnc is excited to bring you the latest news from the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT), which was held virtually from 14-17 of March, 2021.

View all videos

Blinatumomab and inotuzumab in children with R/R B-ALL, w/ Sarah Tasian of @ChildrensPhila: http://ow.ly/8cpu50EF8UI

@PennMedicine @PennMedNews @AACR #AACR21 #HemOnc #Leukemia #Leusm #ALLsm #ImmunoOnc

Ken Anderson closing #COMy21 with his vision for the near future of new #myeloma treatments that will deploy classical MM drugs and targeted agents to induce immunogenic cell death that is then amplified with novel #immune agents #mmsm

3

That is a wrap to yet another fantastic Controversies in #myeloma meeting. Congrats to ⁦@Mohty_EBMT⁩ and co-chairs and looking forward to all being together in person next year #COMy21 #mmsm

Load More...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter